New hope for brain cancer? experimental drug tested in 42 patients
NCT ID NCT05739942
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called [177Lu]Lu-NeoB in 42 people with glioblastoma, a serious brain cancer. For newly diagnosed patients, the drug is given along with standard radiation and chemotherapy. For those whose cancer has returned, it is given alone. The main goal is to find safe doses and check for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Memorial Sloan Kettering Cancer Ctr
New York, New York, 10065, United States
-
Novartis Investigative Site
Dijon, Cote D Or, 21034, France
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
München, 80377, Germany
-
Novartis Investigative Site
Reggio Emilia, RE, 42123, Italy
-
Novartis Investigative Site
Porto, 4200-072, Portugal
-
Novartis Investigative Site
Granada, Andalusia, 18014, Spain
-
Novartis Investigative Site
Badalona, Barcelona, 08916, Spain
-
Novartis Investigative Site
L'Hospitalet de Llobregat, Barcelona, 08907, Spain
-
Novartis Investigative Site
Madrid, 28009, Spain
-
Novartis Investigative Site
Madrid, 28040, Spain
-
Uni of Utah Huntsman Cancer Inst
Salt Lake City, Utah, 84103, United States
-
Univ Hosp Cleveland Medical Center
Cleveland, Ohio, 44106-5028, United States
-
University of California LA
Los Angeles, California, 90095, United States
-
University of Colorado Denver
Aurora, Colorado, 80045, United States